A phase i study of vorinostat in combination with bortezomib in patients with advanced malignancies

Investigational New Drugs

Volumn 31, Issue 6, 2013, Pages 1539-1546

  Schelman, William R ^a   Traynor, Anne M ^a   Holen, Kyle D ^a   Kolesar, Jill M ^a   Attia, Steven ^a   Hoang, Tien ^a   Eickhoff, Jens ^a   Jiang, Zhisheng ^a   Alberti, Dona ^a   Marnocha, Rebecca ^a   Reid, Joel M ^c   Ames, Matthew M ^c   McGovern, Renee M ^c   Espinoza Delgado, Igor ^b   Wright, John J ^b   Wilding, George ^a   Bailey, Howard H ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Bortezomib; Phase I; PS 341; SAHA; Vorinostat

Indexed keywords

4 ANILINO 4 OXOBUTANOIC ACID; BORTEZOMIB; DRUG METABOLITE; UNCLASSIFIED DRUG; VORINOSTAT; VORINOSTAT GLUCURONIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DIAPHORESIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TOXICITY; VOMITING; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRAZINES; YOUNG ADULT;

EID: 84888607613     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0029-6     Document Type: Article

References (37)

1. Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545-579
2. Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343-2350
3. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
4. Amin HM, Saeed S, Alkan S (2001) Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 115:287-297
5. Mitsiades N, Mitsiades CS, Richardson PG et al (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101:4055-4062
6. Mitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101:540-545
7. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101:3236-3239
8. Xu Y, Voelter-Mahlknecht S, Mahlknecht U (2005) The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 15:169-172
9. Yu C, Rahmani M, Almenara J et al (2003) Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63:2118-2126
10. Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC (2003) Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol 30:309-312
11. Zhang C, Richon V, Ni X, Talpur R, Duvic M (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052
12. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97:10014-10019
13. Huang L, Pardee AB (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849-866
14. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497
15. Butler LM, Agus DB, Scher HI et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170
16. Gillenwater AM, Zhong M, Lotan R (2007) Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6:2967-2975
17. Peart MJ, Tainton KM, Ruefli AA et al (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63:4460-4471
18. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600-608
19. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639
20. Nawrocki ST, Carew JS, Pino MS et al (2006) Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66:3773-3781
21. Garcia-Mata R, Gao YS, Sztul E (2002) Hassles with taking out the garbage: aggravating aggresomes. Traffic 3:388-396
22. Yang H, Zonder JA, Dou QP (2009) Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 18:957-971
23. Davies AM, Lara PN Jr, Mack PC, Gandara DR (2007) Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13:s4647-s4651
24. Kondagunta GV, Drucker B, Schwartz L et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720-3725
25. Giuliano M, Lauricella M, Calvaruso G et al (1999) The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 59:5586-5595
26. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765-3774
27. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23(11):1964-1979
28. Place RF, Noonan EJ, Giardina C (2005) HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 6:37
29. Emanuele S, Lauricella M, Carlisi D et al (2007) SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12:1327-1338
30. Carew JS, Medina EC, Esquivel JA 2nd et al (2010) Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 14(10):2448-2459
31. Place RF, Noonan EJ, Giardina C (2005) HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 70:394-406
32. Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egoran MJ (2006) A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA) and its metabolites in human serum. J Chromatogr B Anal Technol Biomed Life Sci 840(2):108-115
33. Siegel D, Hussein M, Belani C et al (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2:31
34. Tsukamoto S, Yokosawa H (2009) Targeting the proteasome pathway. Expert Opin Ther Targets 13:605-621
35. Maki RG, Kraft AS, Scheu K et al (2005) A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103:1431-1438
36. Traynor AM, Dubey S, Eickhoff JC et al (2009) Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4:522-526
37. Ramalingam SS, Parise RA, Ramanathan RK et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13:3605-3610